Prenetics soars on FDA nod to co's unit for genomic profiling test

Prenetics Global

10/01/2023 12:07

** Shares of genetic testing company Prenetics Global Ltd
 PRE.O  up 34.9% at $2.51 before the bell - stock among top
premarket performers across U.S. exchanges
    ** ACT Genomics receives FDA clearance for ACTOnco, the
company's comprehensive genomic profiling test for solid tumors
- PRE
    ** PRE has completed majority stake acquisition of ACT
Genomics to expand its cancer diagnostic services
    ** Clearance for ACTOnco sets the stage for continued R&D
investment in early detection of solid tumors - PRE
    ** This is the first case for an Asia-based co to receive
FDA nod for a genomic profiling test and will advance
personalized cancer care in the continent - PRE
    ** Stock declined 74% in 2022
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))